Aurobindo Pharma: US reopening, traction for COVID vaccine near-term growth opportunity Trading Calls - Equity F&O June 1, 2021Recommendations The most positive development for the last fiscal year has been a sharp reduction in leverage which positions Aurobindo Pharma for capex commitments in the API, vaccine and biosimilars space Anubhav Sahu
